Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RC3H1 divergent transcript (RC3H1-DT), also known as LINC02776, is a long intergenic non-protein coding RNA identified in the human genome. It is formally annotated in gene databases but presently has no described biological functions, disease associations, or established therapeutic relevance[1]. As an lncRNA, it may be involved in regulatory genomic processes, though no specific roles have been published. It should not be confused with protein-coding Rc3h1 (Roquin-1), which regulates immune homeostasis[2]. Key distinctions: - RC3H1-DT/LINC02776 is a lncRNA and not a protein[1]. - Rc3h1 (Roquin-1) is a protein (distinct from the transcript), involved in immune regulation and RNA binding, but this is a separate entity[2]. RC3H1 divergent transcript is therefore not considered a therapeutic target, with no current evidence for functional characterization, disease involvement, or drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RC3H1 divergent transcript (RC3H1-DT).